BioCryst Pharmaceuticals (BCRX) SEC Filings: History & Chart

BioCryst Pharmaceuticals, Inc.(BCRX)

Biotechnology · Durham, NC

$8.10-0.07 (-0.86%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

Durham, NC

435 employees

www.biocryst.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Charles K. Gayer

View full financials

Form	Filing Date	Accepted	Document
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Sep 2, 2026	Sep 2, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 7, 2026	Aug 7, 2026	View filing
S-8	Aug 5, 2026	Aug 5, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
8-K/A	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Jun 29, 2026	Jun 29, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	May 19, 2026	May 19, 2026	View filing
4	May 15, 2026	May 15, 2026	View filing
SC 13G	May 12, 2026	May 12, 2026	View filing

SEC Filings

Recent Filings